pharmaphorum

OCTOBER 6, 2020

These studies suggest BNT162b2 triggers the production of neutralising antibodies and T-cells that target SARS-CoV-2, the coronavirus that causes COVID-19.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. The assumption is SciNeuro will start with Parkinson’s disease and pain in addition to rare genetic diseases, after scaling up staffing. .

RNA 52

RNA Antibody Life Science Protein 52

Roots Analysis

OCTOBER 13, 2023

As a result, in late nineties, the conjugation of drug with biological entities such as antibodies emerged as a possible solution for targeting earlier undruggable entities. However, it was not until 2000 when the first drug conjugate in the form of antibody drug conjugate (ADC) was approved by the USFDA.

Drugs 40

Drugs Antibody RNA Genetics 40

The Pharma Data

NOVEMBER 29, 2020

Naxitamab is a monoclonal antibody that targets GD2, which is found on neuroblastoma and other related tumors. The antibody is designed to destroy GD2-expressing cancer cells by antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). It is an RNA interference (RNAi) therapeutic.

Genetic Disease 52

Genetic Disease Antibody Licensing Licensing 52

The Pharma Data

JANUARY 13, 2021

” The Johnson & Johnson vaccine also would be hardier than either of the already approved vaccines because it relies on DNA technology rather than messenger RNA to prompt an immune system response. More than 90% of participants mounted an immune response within a month, and all had levels of neutralizing antibodies by day 57.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

JULY 6, 2021

Hemophilia is a rare, genetic bleeding disorder in which a person’s blood does not clot properly. New research will be shared on Cablivi ® (caplacizumab-yhdp), a von Willebrand Factor-directed antibody fragment treatment indicated for use in combination with plasma exchange and immunosuppressive therapy for adult patients with aTTP.

Protein 52

Protein RNA Development Marketing 52

The Pharma Data

JULY 6, 2021

But HIV’s ability to mutate isn’t unique among RNA viruses – most viruses develop mutations, or changes in their genetic code, over time. They compared these sequences with the original SARS-CoV-2 genome, cross-checking the genetic changes against their highly networked epitopes. 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccination 52

Vaccination Vaccine Research Immune Response 52

The Pharma Data

JANUARY 21, 2021

.” Osterholm also is worried about new variants reported from South Africa and Brazil, which might “actually have mutations that may in fact compromise the protection we get from the antibody from a vaccine.” People also haven’t been provided clear messaging on the messenger RNA vaccines, Osterholm added.

Vaccination 52

Vaccination Vaccine RNA Genetics 52

XTalks

AUGUST 30, 2022

Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? The return of cell therapy-iPSCs (induced pluripotent stem cells) and genetically altered delivery cells.

Trials 83

Trials Drug Delivery Drugs Gene 83

Pharmaceutical Technology

JUNE 4, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Transcription factors for genetically modified cells. However, not all innovations are equal and nor do they follow a constant upward trend.

Genetics 130

Genetics Gene Expression DNA Antibody 130

XTalks

APRIL 1, 2025

Hemophilia A and B are rare genetic bleeding disorders caused by a deficiency or dysfunction of clotting factors VIII (FVIII) and IX (FIX), respectively. In hemophilia patients, inhibitors are antibodies that interfere with the effectiveness of clotting factor replacement therapies.

FDA Approval 59

FDA Approval RNA Clinical Trials Clinical Trials 59

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

RNA 240

RNA Genetics Vaccination Vaccine 240

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. Both influenza and SARS-CoV-2 have RNA as their genetic material. An RNA genome enables the genetic material to mutate more rapidly.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

XTalks

JUNE 5, 2023

RSV belongs to the family of negative-strand RNA viruses and was first identified in 1955. The genetic material of RSV (respiratory syncytial virus) encodes 11 proteins. AstraZeneca revealed promising Phase III results for its single dose long-acting antibody, nirsevimab , against RSV. How Does Abrysvo Work? billion by 2028.

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

pharmaphorum

NOVEMBER 9, 2020

The vaccine is based on a strand of messenger RNA – a short segment of genetical material that codes for the “Spike” protein found on the surface of the coronavirus. These cause the body to produce antibodies that neutralise the SARS-CoV-2 virus in the event of an infection.

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

pharmaphorum

OCTOBER 12, 2022

Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. The payload, Del Bourgo tell us, is the therapeutic DNA or RNA sequence that will cure or fix damaged cells.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

DECEMBER 23, 2020

In summer, Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder Oxlumo was approved in the European Union and the US. It was the third approval from Alnylam’s pipeline of RNA interference therapeutics to make it to market.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

XTalks

NOVEMBER 7, 2022

Another method to isolate CTCs is by antibody targeting of white blood cells for removal, followed by collection of untagged CTCs. Dr. Bahassi explained that technological advances in genetic sequencing of cfDNA have enabled liquid biopsies and led to marked increase in the detection of therapeutically-targetable mutations.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Roots Analysis

SEPTEMBER 9, 2024

The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. This process initially involves transcription of DNA to messenger RNA (mRNA). The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

pharmaphorum

AUGUST 22, 2022

It’s a naturally occurring process, but you can reprogramme that messenger RNA to do what you want and then put it into the body and use it for a multitude of indications,” Torrance states. The Fund has owned Genmab , a Danish biotechnology company that creates antibody therapies for cancer, for 12 years.

Gene Therapy 102

Gene Therapy Antibody Gene Medicine 102

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. In a study where the antiviral activity of Sunlenca was evaluated in combination with an optimized background regimen, 87.5 percent in the placebo group.

FDA Approval 111

FDA Approval Gene Therapy Gene Clinical Trials 111

The Pharma Data

JANUARY 21, 2021

” But the Pfizer and Moderna vaccines are designed to not only target the spike protein, but to promote the creation of antibodies that will attack it in several different ways, Salvatore said. “The height of the antibody response may be somewhat proportional to how sick you are in the beginning.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

Pharmaceutical Technology

APRIL 27, 2023

When combined with rapid advancement in delivery technologies, mRNA has the potential to lead to breakthroughs in the development of tailored treatment approaches in a wide range of indications from cancer to rare genetic disorders while enabling rapid responses to emerging threats. billion by 2028. billion by 2028. This is what SUT offers.”

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130

Delveinsight

AUGUST 6, 2020

The hATTR diagnosis is mainly dependent on symptoms and can be confirmed via performing tissue biopsies, genetic testing, and imaging studies. hATTR Market: Present Treatment Options. Some of the symptomatic therapies available include loop diuretics, aldosterone antagonists, angiotensin-converting enzyme inhibitors, and beta-blockers.

Protein 52

Protein Gene Silencing Marketing Gene 52

The Pharma Data

MARCH 8, 2022

Actually, these systems could identify viral genetic material (here: Ribonucleic acids/RNAs) and sound the alarm. Proteins of SARS-CoV-2 can alter viral ribonucleic acids in a way, that they become indistinguishable from endogenous RNA. For example, viral RNAs are masked by the addition of a methyl group.

Immune Response 52

Immune Response RNA Protein Genetics 52

XTalks

SEPTEMBER 13, 2021

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

RNA 105

RNA Genetics Genetic Disease Medicine 105

pharmaphorum

DECEMBER 13, 2021

Dormitzer comes from Pfizer, where he was chief scientific officer for RNA and viral vaccines for more than six years. AZ said the deal would go beyond Covid-19 and extend into other RNA-based therapeutics. Like Sanofi, Biogen has invested in AI for RNA-based therapeutics this year, announcing a collaboration with Envisagenics.

RNA 105

RNA Vaccination Vaccine Development 105

Delveinsight

SEPTEMBER 23, 2021

The biotech has evolved a T-cell receptor-like antibody to damage a selected immune checkpoint in oncology. 858 Therapeutics closes USD 60 Million series A round to drug RNA modulation. Now, they are ready for their next venture, which is launching RNA biotech 858 Therapeutics with a USD 60 million Series A fundraising.

RNA 61

RNA Gene Therapy Gene Protein 61

Delveinsight

AUGUST 5, 2021

Sanofi is betting the genetic technology behind the fast development of two highly effective coronavirus shots last year will result in vaccines for other viruses as well as drugs for diseases of the lung and liver, announcing a deal to acquire a research partner Translate Bio for USD 3.2 Sanofi bets USD 3.2 No financial terms were revealed.

Vaccination 98

Vaccination Vaccine Gene Therapy Development 98

Worldwide Clinical Trials

MAY 30, 2024

Biotech Solutions: The Emergence of Various Cell, Gene, & Immunotherapy Options in ALS One up-and-coming area of research is gene therapy, which broadly encompasses any therapeutics that add or edit genetic material. Additionally, researchers are investigating T-cell stimulants (Tregs) and cell-derived neurotrophic growth factor agonists.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

The Pharma Data

JANUARY 10, 2021

CERC-002 is a human anti-LIGHT monoclonal antibody. ILP100 is a genetically engineered Lactobacillus that acts as a small bioreactor on site in the wound, continuously introducing a chemokine, CXCL12, into the wound tissue. The drug is an RNA interference (RNAi) therapeutic.

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

pharmaphorum

JANUARY 17, 2023

The intracellular barriers include endosomal escape, RNA sensors, and endonucleases. Conjugation of targeting ligands such as GalNAc, transferrin receptor antibodies, and lipophilic moieties to siRNAs and ASO have facilitated delivery to liver, muscle, and CNS tissues, respectively, in preclinical or clinical studies.

Vaccination 97

Vaccination Vaccine In-Vivo In-Vitro 97

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

pharmaphorum

JANUARY 20, 2021

The variant that originated in South Africa carries a mutation in the Spike protein that has been shown to reduce antibody recognition and could therefore affect efficacy of new vaccines. The partnership aims to develop a vaccine consisting of regions of genetical material from each coronavirus that causes an immune reaction.

Vaccination 52

Vaccination Vaccine Protein RNA 52

The Pharma Data

DECEMBER 27, 2020

Vir Biotechnology and GlaxoSmithKline dosed the first patient in a new sub-trial of a Phase III study of monoclonal antibody VIR-7831 for hospitalized adults with COVID-19. Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. Here’s a look. COVID-19-Related. Non-COVID-19-Related.

Trials 52

Trials Antibody Gene Therapy Gene 52

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. The level of such antinuclear antibodies often correlates with the severity of disease.

In-Vivo 40

In-Vivo Clinical Trials Clinical Trials FDA Approval 40